IriSight™ Prenatal Analysis
Congenital abnormalities are a significant cause of fetal mortality and morbidity. These abnormalities arise due to chromosomal aberrations during fetal development, many of which are undetectable by standard ultrasound examination. Furthermore, ultrasound screenings carry a false-positive rate of up to 5%, often leading to unnecessary invasive prenatal diagnostic (IPD) procedures, which increase the risk to the fetus.
The IriSight™ Prenatal Analysis test utilizes massively parallel sequencing of cell-free DNA (cfDNA) to detect chromosomal abnormalities with less than 0.08% false-positive rate. This test has demonstrated high clinical utility in the early detection of aneuploidies, abnormal karyotypes, metabolic disorders, neurodevelopmental conditions, and leukemia. By incorporating targeted sequencing of genomic regions associated with 85% of congenital abnormalities, the IriSight™ test provides a highly sensitive and specific approach for prenatal diagnosis.
- Early detection of chromosomal abnormalities, including aneuploidies and microdeletions for postnatal benefits and management
- Identification of high-risk pregnancies, enabling early intervention
Results include a personalized interpretation based on the presence or absence of genetic mutations. Positive results indicate detected chromosomal abnormality, necessitating confirmatory testing through invasive methods such as amniocentesis or chorionic villus sampling (CVS).
A negative result suggests no chromosomal abnormalities within the detection limits of the assay.
Negative (No detectable chromosomal abnormalities)
Amniotic fluid, Cultured cells, parental blood.
Stability (blood)
- Ambient: 3-5 days
- Refrigerated: 5-7 days
If the screening result is positive, the following confirmatory tests are recommended:
- Amniocentesis or Chorionic Villus Sampling (CVS) (to obtain fetal material for karyotyping).
- Fluorescence In Situ Hybridization (FISH) (for rapid detection of chromosomal abnormalities).
- Quantitative Fluorescence PCR (QF-PCR) (for detection of specific aneuploidies).
- Prenat Diagn. 2022 May;42(6):662-685. [PMID: 35170059]
- J Clin Med. 2021 Oct 15;10(20):4739. [PMID: 34682862]
- BMC Pregnancy Childbirth. 2022 Aug 9;22(1):633. [PMID: 35945516]
- Eur J Med Genet. 2022 Feb;65(2):104410. [PMID: 34952236]